As Per The Latest Market research conducted by FMI, the global medical nitroglycerin sprays market is expected to record a CAGR of 3.9% from 2023 to 2033. In 2023, the market size is projected to reach a valuation of USD 110.9 million. By 2033, the valuation is expected to reach USD 163.5 million.
Those with coronary artery disease who experience angina attacks (chest discomfort) can be treated with nitroglycerin lingual spray, which is primarily driving the growth of the nitroglycerin lingual spray market.
To stop angina attacks from occurring, the nitroglycerin lingual spray may also be used just before potential triggers. The category of medications known as vasodilators includes nitroglycerin.
A spray of nitroglycerin is available for application on or under the tongue. Typically, the spray is applied as needed, either 5 to 10 minutes before activities that may cause angina episodes or at the first sign of an attack.
Crucial Growth Factors of the Medical Nitroglycerin Sprays Market:
Economical and No Side Effects:
The spray of nitroglycerin is considered economical and easily accessible. Also, compared to other drugs, it has superior therapeutic effects. It has fewer side effects than traditional medications. In the upcoming years, these reasons are expected to propel the market for nitroglycerin spray.
Available in Different Variations:
Several dose forms of medical nitroglycerin are available in the market, including sublingual tablets, nitroglycerin oral sprays, in-vitro patches, ointments, nitroglycerin mouth sprays, and patches. Owing to this the nitroglycerin oral sprays market as well as the nitroglycerin mouth sprays market is expected to expand.
For instance, nitroglycerin sprays come in a variety of bottle sizes, with contents ranging from 60 doses to 240 doses. Throughout the forecast period, the availability of nitroglycerin spray in a variety of dosage forms and capacities is anticipated to drive the global market.
According to the World Health Organization, the population of adults who are 60 years and above is expected to increase from 900 million in 2015 to 2 billion by 2050. The risk of coronary vascular disease is often very high in the elderly population. Thus, it is projected that growth in the elderly population is likely to propel the nitroglycerin spray market.
Attributes | Value |
---|---|
Medical Nitroglycerin Sprays Value (2022) | USD 106.3 million |
Medical Nitroglycerin Sprays Market Expected Value (2023) | USD 110.9 million |
Medical Nitroglycerin Sprays Market Forecast Value (2033) | USD 163.5 million |
Medical Nitroglycerin Sprays Market Expected CAGR (2023 to 2033) | 3.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to reports, nitroglycerin-treated patients with microvascular angina do not even appear to have made any noticeable advancements. This is because nitroglycerin formulations seem to have a strong resistance to tiny blood arteries. They can drop blood pressure, which may cause difficulties.
Prolonged migraines are a significant cause for concern for migraine sufferers who take more nitroglycerin. For the coming ten years, both of the aforementioned issues are anticipated to stifle growth prospects.
The medical nitroglycerin sprays market recorded a CAGR of 3.8% from 2018 to 2022. The market reached a valuation of USD 106.3 million in 2022. On the other hand, as per the latest market research conducted by FMI, the global medical nitroglycerin sprays market is expected to record a CAGR of 3.9% from 2023 to 2033.
In 2023, the market size is projected to reach a valuation of USD 110.9 million. By 2033, the valuation is expected to be worth USD 163.5 million. Nitroglycerin spray is used to treat angina or chest pain in people with cardiovascular disease.
To avoid angina attacks, it is sometimes administered just before activities that could set them off. A vasodilator is a class of medication that includes nitroglycerin. It works by relaxing the blood vessels, which limits the work the heart must do and consequently reduces the need for oxygen.
Sales of Medical Nitroglycerin Sprays are Likely to be Driven by an Increase in the Prevalence of Angina Pectoris
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
There are numerous dosage forms for medical nitroglycerin, including sublingual pills, in-vitro, sprays, patch therapy, and balms. Also, there are numerous bottle sizes for nitroglycerin sprays, ranging from 60 to 230 dosages.
Moreover, they are less harmful than conventional medicines in terms of side effects. The aforementioned traits are projected to offer considerable opportunities for market expansion during the forecast period.
The Demand for Medical Nitroglycerin Sprays is Likely to be Driven by the Rising Prevalence of Coronary Heart Disease in the United States
For the past ten years, the pharmaceutical business in the United States has experienced rapid growth. Companies like Perrigo Company plc, Evus Health Solutions, and Arimax Pharmaceuticals are well-established in the United States.
An increase in the prevalence of coronary heart disease, which produces acute angina pectoris and calls for the incorporation of efficient treatment techniques, is chiefly responsible for its rise in the country.
Growth in Sales of Medical Nitroglycerin Spray is Likely to be Driven by Growing Healthcare Facilities & Increasing Incidence of Cardiovascular Diseases in Saudi Arabia
Due to an increase in the prevalence of non-communicable diseases and improved healthcare facilities, Saudi Arabia's demand for pharmaceutical products is rising. MNCs own a substantial share of the medicine market in Saudi Arabia, which is expected to be dominated by MNCs in the coming future.
In the upcoming years, it is anticipated that rising cardiovascular disorder incidence, rising healthcare spending, and rising health consciousness are all expected to contribute to the market expansion for medical nitroglycerin sprays.
Growth Outlook of Country-wise Insights:
Country | United States |
---|---|
CAGR (2018 to 2022) | 4.1% |
CAGR (2023 to 2033) | 4.1% |
Valuation (2033) | USD 63.1 million |
Country | United Kingdom |
---|---|
CAGR (2018 to 2022) | 3.4% |
CAGR (2023 to 2033) | 3.9% |
Valuation (2033) | USD 7 million |
Country | China |
---|---|
CAGR (2018 to 2022) | 4.1% |
CAGR (2023 to 2033) | 4.0% |
Valuation (2033) | USD 11.1 million |
Country | Germany |
---|---|
CAGR (2018 to 2022) | 4.2% |
CAGR (2023 to 2033) | 4.3% |
Valuation (2033) | USD 11.5 million |
Country | Canada |
---|---|
CAGR (2018 to 2022) | 2.7% |
CAGR (2023 to 2033) | 4.4% |
Valuation (2033) | USD 10.6 million |
High Usage of Medicinal Nitroglycerin Sprays for Angina Pectoris Prophylaxis
Medicinal nitroglycerin sprays are anticipated to be used frequently for the prevention of angina pectoris. Prophylaxis of the Angina Pectoris segment is expected to record a CAGR of 3.9% over the forecast period.
On the other hand, the acute alleviation of attack (therapy) category recorded a CAGR of 12.9% in 2022. Rising prevalence of acute angina pectoris and the resulting trauma that patients experience are expected to drive this market to new heights in the future.
The primary objectives of significant market players are to expand their product lines and strengthen their portfolios. To increase their customer base, these businesses are concentrating on introducing generic products with low prices and safety features.
Attribute | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2018 to 2022 |
Market Analysis | USD million for Value, Units for Volume |
Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; The Middle East & Africa (MEA) |
Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Türkiye, South Africa, GCC Countries |
Key Market Segments Covered | Application, Dose Capacity, Distribution Channel, Region |
Key Companies Profiled | Perrigo Company Plc.; Evus Health Solutions LLC.; G. Pohl-Boskamp GmbH & Co.; Akrimax Pharmaceuticals LLC; Glenmark Pharmaceuticals Ltd; Dalmia Bros. Pvt. Ltd.; Troikaa; ESPERO BIOPHARMA, INC; Square Pharmaceuticals Ltd; Sun Pharmaceutical Industries Ltd. |
Pricing | Available upon Request |
By 2033, the market will expand at a 3.9% CAGR.
The 2023 market value is USD 110.9 million.
From 2018 to 2022, the market expanded at a 3.8% CAGR.
By 2033, the market will reach USD 163.5 million.
Troikaa, Perrigo Company Plc., and Dalmia Bros. Pvt. Ltd. are some key players.
Explore Healthcare Insights
View Reports